Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A randomized controlled trial
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A randomized controlled trial
Authors
Keywords
Pulmonary function, Lung transplantation, Bronchiolitis, Randomized controlled trials, Cystic fibrosis, Drug therapy, Inflammation, Respiratory infections
Journal
PLoS One
Volume 13, Issue 4, Pages e0193564
Publisher
Public Library of Science (PLoS)
Online
2018-04-07
DOI
10.1371/journal.pone.0193564
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation
- (2016) Kirsten M. Williams et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Chronic lung allograft dysfunction
- (2015) Robin Vos et al. Current Opinion in Organ Transplantation
- A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation
- (2015) Paul A Corris et al. THORAX
- Alemtuzumab in Lung Transplantation: An Open-Label, Randomized, Prospective Single Center Study
- (2014) P. Jaksch et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Are we near to an effective drug treatment for bronchiolitis obliterans?
- (2014) Geert M Verleden et al. EXPERT OPINION ON PHARMACOTHERAPY
- The Registry of the International Society for Heart and Lung Transplantation: Thirty-first Adult Lung and Heart–Lung Transplant Report—2014; Focus Theme: Retransplantation
- (2014) Roger D. Yusen et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Interim Analysis of a Phase II Trial of Montelukast for the Treatment of Bronchiolitis Obliterans Syndrome After HSCT Reveals Immunobiology of Disease
- (2013) Kirsten M. Williams et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Time-dependent changes in the risk of death in pure bronchiolitis obliterans syndrome (BOS)
- (2013) Masaaki Sato et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- A new classification system for chronic lung allograft dysfunction
- (2013) Geert M. Verleden et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- A prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation
- (2012) Peter Jaksch et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- The Registry of the International Society for Heart and Lung Transplantation: 29th Adult Lung and Heart-Lung Transplant Report—2012
- (2012) Jason D. Christie et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Restrictive allograft syndrome (RAS): A novel form of chronic lung allograft dysfunction
- (2011) Masaaki Sato et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot study
- (2011) Geert M. Verleden et al. TRANSPLANT INTERNATIONAL
- Survival after Bronchiolitis Obliterans Syndrome among Bilateral Lung Transplant Recipients
- (2010) C. Ashley Finlen Copeland et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation
- (2010) R. Vos et al. EUROPEAN RESPIRATORY JOURNAL
- The Role of Leukotrienes in Airway Remodeling
- (2009) Anjuli Mehrotra et al. CURRENT MOLECULAR MEDICINE
- Montelukast and bronchial inflammation in asthma: A randomised, double-blind placebo-controlled trial
- (2009) C.F. Ramsay et al. RESPIRATORY MEDICINE
- Efficacy of Total Lymphoid Irradiation in Azithromycin Nonresponsive Chronic Allograft Rejection After Lung Transplantation
- (2009) G.M. Verleden et al. TRANSPLANTATION PROCEEDINGS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started